Medicus Pharma Ltd (NASDAQ:MDCX) Receives Consensus Rating of “Moderate Buy” from Analysts

Medicus Pharma Ltd (NASDAQ:MDCX) has been assigned an average rating of “Moderate Buy” from the five brokerages that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $23.50.

Several equities analysts have recently issued reports on the company. Zacks Research upgraded Medicus Pharma to a “hold” rating in a research report on Monday, September 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Medicus Pharma in a research report on Monday. Finally, D. Boral Capital reissued a “buy” rating and issued a $27.00 price target on shares of Medicus Pharma in a research note on Monday, December 15th.

Hedge Funds Weigh In On Medicus Pharma

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. May Hill Capital LLC acquired a new position in Medicus Pharma in the 2nd quarter valued at $107,000. Guyasuta Investment Advisors Inc. acquired a new position in Medicus Pharma during the 2nd quarter valued at about $230,000. Armistice Capital LLC bought a new position in Medicus Pharma during the 1st quarter worth approximately $4,710,000. SeaCrest Wealth Management LLC acquired a new position in shares of Medicus Pharma in the second quarter valued at about $139,000. Finally, Brave Asset Management Inc. acquired a new position in Medicus Pharma in the third quarter valued at about $46,000.

Medicus Pharma Stock Up 2.0%

MDCX stock opened at $1.55 on Friday. Medicus Pharma has a fifty-two week low of $1.49 and a fifty-two week high of $8.94. The firm’s 50-day simple moving average is $2.11 and its 200 day simple moving average is $2.39. The stock has a market cap of $34.15 million and a PE ratio of -0.72.

Medicus Pharma (NASDAQ:MDCX) last posted its earnings results on Friday, November 14th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.27). Equities analysts forecast that Medicus Pharma will post -1.14 EPS for the current fiscal year.

Medicus Pharma Company Profile

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.